NCT07046221 2025-07-20
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
Fujian Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT03914443 2025-05-31
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
Phase 1 Completed
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT05013697 2021-08-19
TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
Henan Cancer Hospital
Phase 2 Unknown
NCT02778308 2021-04-06
Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma
Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
Phase NA Completed
NCT03963193 2019-05-24
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Henan Cancer Hospital
Phase 2 Unknown
NCT02741856 2018-10-25
SCOPE2
Velindre NHS Trust
Phase 2/3 Unknown
NCT00450203 2016-12-01
ST03
Medical Research Council
Phase 2/3 Unknown
NCT00980603 2009-09-21
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT00559351 2007-11-16
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
Ministry of Scientific Research and Information Technology, Poland
Phase 3 Terminated